1 Fahad, U. M. (2019) Breast Cancer: Current Perspectives on the Disease Status. ADV EXP MED BIOL. 1152, 51-64
2 Parker, J. S., Mullins, M., Cheang, M. C., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., Quackenbush, J. F., Stijleman, I. J., Palazzo, J., Marron, J. S., Nobel, A. B., Mardis, E., Nielsen, T. O., Ellis, M. J., Perou, C. M. and Bernard, P. S. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J CLIN ONCOL. 27, 1160-1167
3 Jiang, Y. Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K. D., Liu, Y. R., Yu, Y., Zheng, Y., Li, X., Zhang, C., Hu, P., Zhang, J., Hua, Q., Zhang, J., Hou, W., Ren, L., Bao, D., Li, B., Yang, J., Yao, L., Zuo, W. J., Zhao, S., Gong, Y., Ren, Y. X., Zhao, Y. X., Yang, Y. S., Niu, Z., Cao, Z. G., Stover, D. G., Verschraegen, C., Kaklamani, V., Daemen, A., Benson, J. R., Takabe, K., Bai, F., Li, D. Q., Wang, P., Shi, L., Huang, W. and Shao, Z. M. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. CANCER CELL. 35, 428-440
4 Wang, H., Liu, X. Y., Jiang, Y. Z. and Shao, Z. M. (2020) [Challenges and countermeasures in the treatment of luminal breast cancer]. Zhonghua Zhong Liu Za Zhi. 42, 192-196
5 Li, Z. H., Hu, P. H., Tu, J. H. and Yu, N. S. (2016) Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 7, 65024-65033
6 Gluz, O. (2020) Luminal Breast Cancer: The Head of Janus in Breast Oncology. Breast Care (Basel). 15, 325-326
7 Franzoi, M. A. and de Azambuja, E. (2020) Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? ESMO Open. 5, e1112
8 Emens, L. A., Adams, S., Barrios, C. H., Dieras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A., Winer, E. P., Patel, S., Henschel, V., Swat, A., Kaul, M., Molinero, L., Patel, S., Chui, S. Y. and Schmid, P. (2021) First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. ANN ONCOL. 32, 983-993
9 Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V., Henschel, V., Molinero, L., Chui, S. Y., Maiya, V., Husain, A., Winer, E. P., Loi, S. and Emens, L. A. (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOL. 21, 44-59
10 Nanda, R., Chow, L. Q., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., Karantza, V. and Buisseret, L. (2016) Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. J CLIN ONCOL. 34, 2460-2467
11 Schmid, P., Salgado, R., Park, Y. H., Munoz-Couselo, E., Kim, S. B., Sohn, J., Im, S. A., Foukakis, T., Kuemmel, S., Dent, R., Yin, L., Wang, A., Tryfonidis, K., Karantza, V., Cortes, J. and Loi, S. (2020) Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. ANN ONCOL. 31, 569-581
12 Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., Liu, M. C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H. S., Tan, A. R., Jia, L., Ding, Y., Karantza, V. and Schmid, P. (2019) Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. ANN ONCOL. 30, 405-411
13 Winer, E. P., Lipatov, O., Im, S. A., Goncalves, A., Munoz-Couselo, E., Lee, K. S., Schmid, P., Tamura, K., Testa, L., Witzel, I., Ohtani, S., Turner, N., Zambelli, S., Harbeck, N., Andre, F., Dent, R., Zhou, X., Karantza, V., Mejia, J. and Cortes, J. (2021) Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. LANCET ONCOL. 22, 499-511
14 Gong, Y., Ji, P., Yang, Y. S., Xie, S., Yu, T. J., Xiao, Y., Jin, M. L., Ma, D., Guo, L. W., Pei, Y. C., Chai, W. J., Li, D. Q., Bai, F., Bertucci, F., Hu, X., Jiang, Y. Z. and Shao, Z. M. (2021) Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. CELL METAB. 33, 51-64
15 Zhao, S., Zuo, W. J., Shao, Z. M. and Jiang, Y. Z. (2020) Molecular subtypes and precision treatment of triple-negative breast cancer. Ann Transl Med. 8, 499
16 Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E. and Gfeller, D. (2017) Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. ELIFE. 6
17 Loo, L., Williams, M. and Hernandez, B. Y. (2019) The high and heterogeneous burden of breast cancer in Hawaii: A unique multiethnic U.S. Population. CANCER EPIDEMIOL. 58, 71-76
18 Corso, G., Magnoni, F., Provenzano, E., Girardi, A., Iorfida, M., De Scalzi, A. M., Invento, A., Colleoni, M., Cassano, E., Trentin, C., Gullo, R. L., Pravettoni, G., Gilardi, L., Grana, C. M., Intra, M., Galimberti, V., Veronesi, P., De Lorenzi, F. and Leonardi, M. C. (2020) Multicentric breast cancer with heterogeneous histopathology: a multidisciplinary review. FUTURE ONCOL. 16, 395-412
19 Leong, S. P., Shen, Z. Z., Liu, T. J., Agarwal, G., Tajima, T., Paik, N. S., Sandelin, K., Derossis, A., Cody, H. and Foulkes, W. D. (2010) Is breast cancer the same disease in Asian and Western countries? WORLD J SURG. 34, 2308-2324
20 Puppe, J., Seifert, T., Eichler, C., Pilch, H., Mallmann, P. and Malter, W. (2020) Genomic Signatures in Luminal Breast Cancer. Breast Care (Basel). 15, 355-365
21 Bediaga, N. G., Beristain, E., Calvo, B., Viguri, M. A., Gutierrez-Corres, B., Rezola, R., Ruiz-Diaz, I., Guerra, I. and de Pancorbo, M. M. (2016) Luminal B breast cancer subtype displays a dicotomic epigenetic pattern. Springerplus. 5, 623
22 Baker, H. (2015) 21-gene assay identifies patients who can avoid chemotherapy. LANCET ONCOL. 16, e531
23 Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. J., Dees, E. C., Perez, E. A., Olson, J. J., Zujewski, J., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P., Keane, M. M., Gomez, M. H., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D. L., Kaklamani, V. G., Atkins, J. N., Berenberg, J. L. and Sledge, G. W. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 373, 2005-2014
24 van der Hoeven, J. J. (2017) [70-Gene signature as an aid to treatment decisions in early-stage breast cancer]. Ned Tijdschr Geneeskd. 161, D1369
25 Dieras, V., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J. P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., Jalving, M., Oprean, C., Palacova, M., Park, Y. H., Shparyk, Y., Yanez, E., Khandelwal, N., Kundu, M. G., Dudley, M., Ratajczak, C. K., Maag, D. and Arun, B. K. (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. LANCET ONCOL. 21, 1269-1282
26 Pantelidou, C., Sonzogni, O., De Oliveria, T. M., Mehta, A. K., Kothari, A., Wang, D., Visal, T., Li, M. K., Pinto, J., Castrillon, J. A., Cheney, E. M., Bouwman, P., Jonkers, J., Rottenberg, S., Guerriero, J. L., Wulf, G. M. and Shapiro, G. I. (2019) PARP Inhibitor Efficacy Depends on CD8(+) T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. CANCER DISCOV. 9, 722-737
27 Werner, H. and Sarfstein, R. (2014) Transcriptional and epigenetic control of IGF1R gene expression: implications in metabolism and cancer. GROWTH HORM IGF RES. 24, 112-118
28 Schanzer, J. M., Wartha, K., Moessner, E., Hosse, R. J., Moser, S., Croasdale, R., Trochanowska, H., Shao, C., Wang, P., Shi, L., Weinzierl, T., Rieder, N., Bacac, M., Ries, C. H., Kettenberger, H., Schlothauer, T., Friess, T., Umana, P. and Klein, C. (2016) XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer. MABS-AUSTIN. 8, 811-827
29 Zhang, Q., Li, T., Wang, Z., Kuang, X., Shao, N. and Lin, Y. (2020) lncRNA NR2F1-AS1 promotes breast cancer angiogenesis through activating IGF-1/IGF-1R/ERK pathway. J CELL MOL MED. 24, 8236-8247
30 Wang, P., Zeng, Z., Lin, C., Wang, J., Xu, W., Ma, W., Xiang, Q., Liu, H. and Liu, S. L. (2020) Thrombospondin-1 as a Potential Therapeutic Target: Multiple Roles in Cancers. Curr Pharm Des. 26, 2116-2136
31 Liu, X., Xu, D., Liu, Z., Li, Y., Zhang, C., Gong, Y., Jiang, Y. and Xing, B. (2020) THBS1 facilitates colorectal liver metastasis through enhancing epithelial-mesenchymal transition. CLIN TRANSL ONCOL. 22, 1730-1740
32 Shen, J., Cao, B., Wang, Y., Ma, C., Zeng, Z., Liu, L., Li, X., Tao, D., Gong, J. and Xie, D. (2018) Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer Res. 37, 175
33 Yamashita, N., Long, M., Fushimi, A., Yamamoto, M., Hata, T., Hagiwara, M., Bhattacharya, A., Hu, Q., Wong, K. K., Liu, S. and Kufe, D. (2021) MUC1-C integrates activation of the IFN-gamma pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer. J IMMUNOTHER CANCER. 9
34 De Angelis, C., Fu, X., Cataldo, M. L., Nardone, A., Pereira, R., Veeraraghavan, J., Nanda, S., Qin, L., Sethunath, V., Wang, T., Hilsenbeck, S. G., Benelli, M., Migliaccio, I., Guarducci, C., Malorni, L., Litchfield, L. M., Liu, J., Donaldson, J., Selenica, P., Brown, D. N., Weigelt, B., Reis-Filho, J. S., Park, B. H., Hurvitz, S. A., Slamon, D. J., Rimawi, M. F., Jansen, V. M., Jeselsohn, R., Osborne, C. K. and Schiff, R. (2021) Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. CLIN CANCER RES. 27, 4939
35 Trimboli, A. J., Cantemir-Stone, C. Z., Li, F., Wallace, J. A., Merchant, A., Creasap, N., Thompson, J. C., Caserta, E., Wang, H., Chong, J. L., Naidu, S., Wei, G., Sharma, S. M., Stephens, J. A., Fernandez, S. A., Gurcan, M. N., Weinstein, M. B., Barsky, S. H., Yee, L., Rosol, T. J., Stromberg, P. C., Robinson, M. L., Pepin, F., Hallett, M., Park, M., Ostrowski, M. C. and Leone, G. (2009) Pten in stromal fibroblasts suppresses mammary epithelial tumours. NATURE. 461, 1084-1091
36 Ohno, S., Tachibana, M., Fujii, T., Ueda, S., Kubota, H. and Nagasue, N. (2002) Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. INT J CANCER. 97, 770-774
37 Xu, M., Li, Y., Li, W., Zhao, Q., Zhang, Q., Le K, Huang, Z. and Yi, P. (2020) Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. Front Med (Lausanne). 7, 64
38 Guinney, J., Dienstmann, R., Wang, X., de Reynies, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., Bot, B. M., Morris, J. S., Simon, I. M., Gerster, S., Fessler, E., De Sousa, E. M. F., Missiaglia, E., Ramay, H., Barras, D., Homicsko, K., Maru, D., Manyam, G. C., Broom, B., Boige, V., Perez-Villamil, B., Laderas, T., Salazar, R., Gray, J. W., Hanahan, D., Tabernero, J., Bernards, R., Friend, S. H., Laurent-Puig, P., Medema, J. P., Sadanandam, A., Wessels, L., Delorenzi, M., Kopetz, S., Vermeulen, L. and Tejpar, S. (2015) The consensus molecular subtypes of colorectal cancer. NAT MED. 21, 1350-1356
39 Wu, S. Z. and Swarbrick, A. (2021) Single-cell advances in stromal-leukocyte interactions in cancer. IMMUNOL REV. 302, 286-298
40 Mhaidly, R. and Mechta-Grigoriou, F. (2021) Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. IMMUNOL REV. 302, 259-272
41 Chen, P. Y., Wei, W. F., Wu, H. Z., Fan, L. S. and Wang, W. (2021) Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling. FRONT IMMUNOL. 12, 671595
42 Primac, I., Maquoi, E., Blacher, S., Heljasvaara, R., Van Deun, J., Smeland, H. Y., Canale, A., Louis, T., Stuhr, L., Sounni, N. E., Cataldo, D., Pihlajaniemi, T., Pequeux, C., De Wever, O., Gullberg, D. and Noel, A. (2019) Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression. J CLIN INVEST. 129, 4609-4628
43 Camorani, S., Hill, B. S., Collina, F., Gargiulo, S., Napolitano, M., Cantile, M., Di Bonito, M., Botti, G., Fedele, M., Zannetti, A. and Cerchia, L. (2018) Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRbeta aptamer. THERANOSTICS. 8, 5178-5199
44 Camorani, S., Passariello, M., Agnello, L., Esposito, S., Collina, F., Cantile, M., Di Bonito, M., Ulasov, I. V., Fedele, M., Zannetti, A., De Lorenzo, C. and Cerchia, L. (2020) Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer. J Exp Clin Cancer Res. 39, 180
45 Keenan, T. E. and Tolaney, S. M. (2020) Role of Immunotherapy in Triple-Negative Breast Cancer. J Natl Compr Canc Netw. 18, 479-489
46 Katz, H. and Alsharedi, M. (2017) Immunotherapy in triple-negative breast cancer. MED ONCOL. 35, 13
47 Dieci, M. V., Guarneri, V., Tosi, A., Bisagni, G., Musolino, A., Spazzapan, S., Moretti, G., Vernaci, G. M., Griguolo, G., Giarratano, T., Urso, L., Schiavi, F., Pinato, C., Magni, G., Lo, M. M., De Salvo, G. L., Rosato, A. and Conte, P. (2022) Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. CLIN CANCER RES. 28, 308-317